A common polymorphism G-50T in cytochrome P450 2J2 gene is associated with increased risk of essential hypertension in a Russian population

Disease Markers

Volumn 24, Issue 2, 2008, Pages 119-126

  Polonikov, Alexey V ^a   Ivanov, Vladimir P ^a   Solodilova, Maria A ^a   Khoroshaya, Irina V ^a   Kozhuhov, Mikhail A ^b   Ivakin, Vladimir E ^c   Katargina, Ludmila N ^c   Kolesnikova, Ol'ga E ^b  

^a KURSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^b Kursk Regional Clinical Hospital   (Russian Federation)

^c Kursk Emergency Medicine Hospital   (Russian Federation)

Author keywords

Arachidonic acid metabolism; Case control studies; Cytochrome P450 CYP2J2; Disease susceptibility; Essential hypertension; Single nucleotide polymorphism

Indexed keywords

ARACHIDONIC ACID; CYTOCHROME P450 2J2; CYTOCHROME P450 EPOXYGENASE; DNA; UNCLASSIFIED DRUG;

ALLELE; ARACHIDONIC ACID METABOLISM; ARTICLE; CONTROLLED STUDY; CYP2J2 GENE; DISEASE PREDISPOSITION; ESSENTIAL HYPERTENSION; FAMILY HISTORY; GENDER; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATHOGENESIS; POPULATION RISK; PRIORITY JOURNAL; RISK ASSESSMENT; RUSSIAN FEDERATION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 38349092381     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2008/626430     Document Type: Article

References (38)

1. A.W. Dreisbach, S. Japa, A. Sigel, M.B. Parenti, A.E. Hess, S.L. Srinouanprachanh et al., The prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension, Am J Hypertens 18 (2005), 1276-1281.
2. B. Woolf, On estimating the relation between blood group and disease, Ann Hum Genet 19 (1955), 251-253.
3. B. Yang, L. Graham, S. Dikalov, R.P. Mason, J.R. Falck, J.K. Liao and D.C. Zeldin, Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells, Mol Pharmacol 60 (2001), 310-320.
4. C. Moreno, K.G. Maier, K.M. Hoagland, M. Yu and R.J. Roman, Abnormal pressure-natriuresis in hypertension: role of cytochrome P450 metabolites of arachidonic acid, Am J Hypertens 14 (2001), 90-97.
5. C.P. Martucci and J. Fishman, P450 enzymes of estrogen metabolism, Pharmacol Ther 57 (1993), 237-257.
6. C.S. Carlson, M.A. Eberle, L. Kruglyak and D.A. Nickerson, Mapping complex disease loci in whole-genome association studies, Nature 249 (2004), 446-452.
7. D.C. Zeldin, Epoxygenase pathways of arachidonic acid metabolism, J Biol Chem 276 (2001), 36059-36062.
8. D.R. Nelson, L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman et al., P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics 6 (1996), 1-42.
9. D. Zhu, M. Bousamra, D.C. Zeldin, J.R. Falck, M. Townsley, D.R. Harder et al., Epoxyeicosatrienoic acids constrict isolated pressurized rabbit pulmonary arteries, Am J Physiol Lung Cell Mol Physiol 278 (2000), 335-343.
10. E.S. Lander and N.J. Schork, Genetic dissection of complex traits, Science 265 (1994), 2037-2048.
11. F. Cambien, O. Poirier, V. Nicaud, S.M. Herrmann, C. Mallet, S. Ricard et al., Sequence diversity in 36 candidate genes for cardiovascular disorders, Am J Hum Genet 65 (1999), 183-191.
12. G.C.L. Johnson and J.A. Todd, Strategies in complex disease mapping, Curr Opin Genet Dev 10 (2000), 330-334.
13. I. Fleming, B. Fisslthaler, U.R. Michaelis, L. Kiss, R. Popp and R. Busse, The coronary endothelium-derived hyperpolarizing factor (EDHF) stimulates multiple signalling pathways and proliferation in vascular cells, Pflugers Arch 442 (2001), 511-518.
14. I. Fleming, Cytochrome P450 and vascular homeostasis, Circ Res 89 (2001), 753-762.
15. J. Altmuller, L.J. Palmer, G. Fischer, H. Scherb and M. Wjst, Genome wide scans of complex human diseases: true linkage is hard to find, Am J Hum Genet 69 (2001), 936-950.
16. J.C. McGiff, Cytochrome P450 metabolism of arachidonic acid, Annu Rev Pharmacol Toxicol 31 (1991), 339-369.
17. J.H. Capdevila, J.R. Falck and R.C. Harris, Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase, J Lipid Res 41 (2000), 163-181.
18. J.K. Chen, J. Capdevila and R.C. Harris, Cytochrome P450 epoxygenase metabolism of arachidonic acid inhibits apoptosis, Mol Cell Biol 21 (2001), 6322-6331.
19. J.N. Hirschhorn, K. Lohmueller, E. Byrne and K. Hirschhorn, A comprehensive review of genetic association studies, Genet Med 4 (2002), 45-61.
20. J. Pinsonneault and W. Sadee, Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome, AAPS Pharm Sci 5 (2003), E29.
21. K.G. Maier and R.J. Roman, Cytochrome P450 metabolites of arachidonic acid in the control of renal function, Curr Opin Nephrol Hypertens 10 (2001), 81-87.
22. K.M. Hoagland, A.K. Flasch and R.J. Roman, Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats, Hypertension 42 (2003), 669-673.
23. K. Takahashi, J. Capdevila, A. Karara, J.R. Falck, H.R. Jacobson and K.F. Badr, Cytochrome P-450 arachidonate metabolites in rat kidney: characterization and hemodynamic responses, Am J Physiol 258 (1990), 781-789.
24. L.A. Weiss, L. Pan, M. Abney and C. Ober, The sex-specific genetic architecture of quantitative traits in humans, Nat Genet 38 (2006), 218-222.
25. L.M. King, J. Ma, S. Srettabunjong, J. Graves, J.A. Bradbury, L. Li et al., Cloning of CYP2J2 gene and identification of functional polymorphisms, Mol Pharmacol 61 (2002), 840-852.
26. L.M. King, J.V. Gainer, G.L. David, D. Dai, J.A. Goldstein, N.J. Brownand D.C. Zeldin, Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension, Pharmacogenet Genomics 15 (2005), 7-13.
27. L.R. Cardon and J.I. Bell, Association study designs for complex diseases, Nat Rev Genet 2 (2001), 91-99.
28. M. Alonso-Galicia, K.G. Maier, A.S. Greene, A.W. Cowley Jr and R.J. Roman, Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II, Am J Physiol Regul Integr Comp Physiol 283 (2002), 60-68.
29. M.R. Uddin, M.M. Muthalif, N.A. Karzoun, I.F. Bentner and K.U. Malik, Cytochrome P-450 metabolites mediate norepinephrine-induced mitogenic signaling, Hypertension 31 (1998), 242-247.
30. M. Spiecker, H. Darius, T. Hankeln, M. Soufi, A.M. Sattler, J.R. Schaefer et al., Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2, Circulation 110 (2004), 2132-2136.
31. P.E. Scarborough, J. Ma, W. Qu and D.C. Zeldin, P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues, Drug Metab Rev 31 (1999), 205-234.
32. R.J. Roman, P-450 metabolites of arachidonic acid in the control of cardiovascular function, Physiol Rev 82 (2002), 131-185.
33. S. Taddei, D. Versari, A. Cipriano, L. Ghiadoni, F. Galetta, F. Franzoni et al., Identification of a cytochrome P450 2C9-derived endothelium-derived hyperpolarizing factor in essential hypertensive patients, J Am Coll Cardiol 48 (2006), 508-515.
34. S. Wu, C.R. Moomaw, K.B. Tomer, J.R. Falck and D.C. Zeldin, Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart, J Biol Chem 271 (1996), 3460-3468.
35. T. Katoh, K. Takahashi, J. Capdevila, A. Karara, J.R. Falck, H.R. Jacobson and K.F. Badr, Glomerular stereospecific synthesis and hemodynamic actions of 8,9-epoxyeicosatrienoic acid in rat kidney, Am J Physiol 261 (1991), 578-586.
36. W.B. Campbell and D.R. Harder, Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone, Circ Res 84 (1999), 484-488.
37. W.L. Henrich, J.R. Falck and W.B. Campbell, Inhibition of renin release by 14,15-epoxyeicosatrienoic acid in renal cortical slices, Am J Physiol 258 (1990), 269-274.
38. X. Fang, T.L. Kaduce, N.L. Weintraub, S. Harmon, L.M. Teesch, C. Morisseau et al., Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition, J Biol Chem 276 (2001), 14867-14874.